Özge has a MSc. in Molecular Genetics from the University of Leicester and a PhD in Developmental Biology from Queen Mary University of London. She worked as a Post-doctoral Research Associate at the University of Leicester for six years in the field of Behavioural Neurology before moving into science communication. She worked as the Research Communication Officer at a London based charity for almost two years.
Treating idiopathic pulmonary fibrosis (IPF) patients with the anti-IPF drug Esbriet (pirfenidone) before and after lung surgery could be protective against acute exacerbation, or worsening of IPF, a life-threatening ... Read more
Treatment with Ofev (nintedanib) is associated with stabilization of lung function in patients with idiopathic pulmonary fibrosis (IPF) according to a study published in the scientific journal Respiration.
... Read more
Researchers are one step closer to understanding the molecular mechanism of action of pirfenidone, the anti fibrotic drug for the treatment of pulmonary fibrosis. This may help improve the ... Read more
The U.S. Department of Defense granted $11.5 million to researchers at National Jewish Health, one of the leading respiratory hospitals in the country, for two research projects investigating lung ... Read more
Pulmatrix, a clinical stage biopharmaceutical company, recently released an animated life sciences video describing their new dry powder inhaler system called Isperse for lung disease patients.
... Read more
OFEV (nintedanib) is effective for a wide range of idiopathic pulmonary fibrosis (IPF) patients according to Boehringer Ingelheim, the company that developed the drug.
Average ... Read more
Pin It on Pinterest